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Résumé en
anglais
Myeloproliferative neoplasms (MPN) are chronic disorders that can sometimes evolve
into accelerated or leukemic phases. We retrospectively identified 122 patients with
such blastic phases. The overall median survival was four months: 10.2 months for
patients treated with intensive treatments compared to three months for best
supportive care (p = .005). Azacytidine, intensive chemotherapies, or allogeneic stem
cell transplantation gave the highest median survivals with 9, 10.2, and 19.4 months,
respectively. Accelerated phases (AP) had a longer median survival compared to acute
leukemia (4.8 months vs. 3.1 months; p = .02). In this retrospective and observational
study, we observe that the longest survivals are seen in patients eligible for intensive
treatments. Azacytidine shows interesting results in patients non-fit for intensive
chemotherapy. Supportive care should probably be restricted to elderly patients and
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